Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 21

Sort by

Sort Order Select

Meeting Abstracts

1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

ANNE-DITTE TERMANNSEN, ANNEMARIE R. VARMING, GITTE S.H. STAGE HANSEN, NATASJA BJERRE, FREDERIK PERSSON, JONATAN I. BAGGER, SR., NILS B. JØRGENSEN, NANA F. HEMPLER, KRISTINE FAERCH, JONAS S. QUIST

Diabetes 2023;72(Supplement_1):1613-P

https://doi.org/10.2337/db23-1613-P

Published: 20 June 2023

View article titled, 1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

Meeting Abstracts

1319-P: Vascular Multimorbidity in Danish Persons with Type 2 Diabetes Is Decreasing, Contributing to Mortality Decline

BENDIX CARSTENSEN, KIM K.B. CLEMMENSEN, VANJA KOSJERINA, FREDERIK PERSSON

Diabetes 2023;72(Supplement_1):1319-P

https://doi.org/10.2337/db23-1319-P

Published: 20 June 2023

View article titled, 1319-P: Vascular Multimorbidity in Danish Persons with Type 2 Diabetes Is Decreasing, Contributing to Mortality Decline

Meeting Abstracts

396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes

ELISABETH BUUR STOUGAARD, PETER L. KRISTENSEN, URD KIELGAST, SR., HENRIK U. ANDERSEN, YASMIN H. HAMID, PETER GÆDE, ESBEN SØNDERGAARD, GRY DØRFLINGER, KAREN K. FJELDBORG, KLAVS W. HANSEN, HENRIK H. THOMSEN, THURAYA AL-IMARI, MICHAEL RØDER, PETER ROSSING, FREDERIK PERSSON

Diabetes 2022;71(Supplement_1):396-P

https://doi.org/10.2337/db22-396-P

Published: 01 June 2022

View article titled, 396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes

Meeting Abstracts

866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study

FREDERIK PERSSON, PETER ROSSING, NIELS JONGS, GLENN M. CHERTOW, FAN FAN HOU, PRIYA VART, JOHN J. MCMURRAY, RICARDO CORREA-ROTTER, BERGUR STEFANSSON, ROBERT D. TOTO, ANNA MARIA LANGKILDE, DAVID C. WHEELER, HIDDO L. HEERSPINK, DAPA-CKD TRIAL COMMITTEES AND INVESTIGATORS

Diabetes 2022;71(Supplement_1):866-P

https://doi.org/10.2337/db22-866-P

Published: 01 June 2022

View article titled, 866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study

Meeting Abstracts

21-OR: Optimization of Albuminuria Lowering Treatment by Crossover Rotation to Four Different Drug Classes

VIKTOR ROTBAIN CUROVIC, MARJOLEIN Y.A. KROONEN, NIELS JONGS, TAHA SEN, EMILIE ZOBEL, TINE W. HANSEN, GOZEWIJN D. LAVERMAN, ADRIAAN KOOY, FREDERIK PERSSON, PETER ROSSING, HIDDO L. HEERSPINK

Diabetes 2022;71(Supplement_1):21-OR

https://doi.org/10.2337/db22-21-OR

Published: 01 June 2022

View article titled, 21-OR: Optimization of Albuminuria Lowering Treatment by Crossover Rotation to Four Different Drug Classes

Meeting Abstracts

317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial

FREDERIK PERSSON, PETER ROSSING, PRIYA VART, GLENN M. CHERTOW, FAN FAN HOU, JOHN J. MCMURRAY, RICARDO CORREA-ROTTER, HARPREET S. BAJAJ, BERGUR STEFANSSON, ROBERT D. TOTO, ANNA MARIA LANGKILDE, DAVID C. WHEELER, HIDDO L. HEERSPINK, DAPA-CKD STUDY GROUP

Diabetes 2021;70(Supplement_1):317-OR

https://doi.org/10.2337/db21-317-OR

Published: 01 June 2021

View article titled, 317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial

Meeting Abstracts

380-P: Endothelial Glycocalyx Dimensions and Cardiovascular Risk Factors in Type 1 Diabetes

ELISABETH BUUR STOUGAARD, SIGNE WINTHER, HANAN AMADID, MARIE FRIMODT-MOELLER, FREDERIK PERSSON, TINE W. HANSEN, PETER ROSSING

Diabetes 2021;70(Supplement_1):380-P

https://doi.org/10.2337/db21-380-P

Published: 01 June 2021

View article titled, 380-P: Endothelial Glycocalyx Dimensions and Cardiovascular Risk Factors in Type 1 Diabetes

Journal Articles

Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture

Peter Rossing, Frederik Persson, Marie Frimodt-Møller, Tine Willum Hansen

Diabetes 2021;70(1):39–50

https://doi.org/10.2337/dbi19-0038

Published: 15 December 2020

View article titled, Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture

Meeting Abstracts

1615-P: Predicting End-Stage Kidney Disease in Type 1 Diabetes

DORTE VISTISEN, GREGERS S. ANDERSEN, ADAM HULMAN, STUART MCGURNAGHAN, HELEN M. COLHOUN, JAN ERIK HENRIKSEN, REIMAR W. THOMSEN, FREDERIK PERSSON, PETER ROSSING, MARIT E. JØRGENSEN

Diabetes 2020;69(Supplement_1):1615-P

https://doi.org/10.2337/db20-1615-P

Published: 01 June 2020

View article titled, 1615-P: Predicting End-Stage Kidney Disease in Type 1 Diabetes

Meeting Abstracts

844-P: Effects of Dapagliflozin, Metformin, or Exercise on Plasma Glucagon Concentrations in Individuals with Prediabetes: The PRE-D Trial

KIM K.B. CLEMMENSEN, MARTIN B. BLOND, HANAN AMADID, LEA B. NIELSEN, DORTE VISTISEN, KRISTIAN KARSTOFT, FREDERIK PERSSON, MATHIAS RIED-LARSEN, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN, SIGNE S. TOREKOV, JONAS S. QUIST, MARIT E. JØRGENSEN, KRISTINE FÆRCH

Diabetes 2020;69(Supplement_1):844-P

https://doi.org/10.2337/db20-844-P

Published: 01 June 2020

View article titled, 844-P: Effects of Dapagliflozin, Metformin, or Exercise on Plasma Glucagon Concentrations in Individuals with Prediabetes: The PRE-D Trial

Meeting Abstracts

845-P: Changes in Plasma Levels of Liver Enzymes in Response to Dapagliflozin, Metformin, or Exercise in People with Prediabetes: The PRE-D Trial

MARTIN B. BLOND, KIM K. CLEMMENSEN, HANAN AMADID, LEA B. NIELSEN, MATHIAS RIED-LARSEN, KRISTIAN KARSTOFT, FREDERIK PERSSON, MARIT E. JØRGENSEN, KRISTINE FAERCH

Diabetes 2020;69(Supplement_1):845-P

https://doi.org/10.2337/db20-845-P

Published: 01 June 2020

View article titled, 845-P: Changes in Plasma Levels of Liver Enzymes in Response to Dapagliflozin, Metformin, or Exercise in People with Prediabetes: The PRE-D Trial

Meeting Abstracts

794-P: “The Tool Created a Chance to Discuss Topics You Don’t Normally Address in Diabetes Consultations”: A Study of Using Patient-Reported Outcomes to Promote Person-Centered Care and Psychosocial Support

LENE E. JOENSEN, ASTRID A. SCHULTZ, KRISTOFFER P. MADSEN, FREDERIK PERSSON, KIRSTEN NØRGAARD, INGRID WILLAING

Diabetes 2020;69(Supplement_1):794-P

https://doi.org/10.2337/db20-794-P

Published: 01 June 2020

View article titled, 794-P: “The Tool Created a Chance to Discuss Topics You Don’t Normally Address in Diabetes Consultations”: A Study of Using Patient-Reported Outcomes to Promote Person-Centered Care and Psychosocial Support

Meeting Abstracts

137-OR: Trends in Lipid Levels Relative to Lipid-Lowering Drug Use among Danish Type 2 Diabetes Subjects

HANAN AMADID, MARIA BEKKER-NIELSEN DUNBAR, PERNILLE F. RØNN, JAKOB S. KNUDSEN, BENDIX CARSTENSEN, FREDERIK PERSSON, MARIT E. JØRGENSEN

Diabetes 2020;69(Supplement_1):137-OR

https://doi.org/10.2337/db20-137-OR

Published: 01 June 2020

View article titled, 137-OR: Trends in Lipid Levels Relative to Lipid-Lowering Drug Use among Danish Type 2 Diabetes Subjects

Meeting Abstracts

1467-P: National Trends in the Use of Lipid-Lowering Drugs among Type 2 Diabetes Patients in Denmark from 1997 to 2017

PERNILLE F RØNN, BENDIX CARSTENSEN, JAKOB S. KNUDSEN, FREDERIK PERSSON, MARIT E JØRGENSEN

Diabetes 2019;68(Supplement_1):1467-P

https://doi.org/10.2337/db19-1467-P

Published: 01 June 2019

View article titled, 1467-P: National Trends in the Use of Lipid-Lowering Drugs among Type 2 Diabetes Patients in Denmark from 1997 to 2017

Meeting Abstracts

1196-P: The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D)

DANIËL H. VAN RAALTE, PETTER BJORNSTAD, FREDERIK PERSSON, RITA CASTRO, STELLA WANG, DAVID R. POWELL, HIDDO L. HEERSPINK, DAVID CHERNEY

Diabetes 2019;68(Supplement_1):1196-P

https://doi.org/10.2337/db19-1196-P

Published: 01 June 2019

View article titled, 1196-P: The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D)

Meeting Abstracts

901-P: Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

KRISTINE FÆRCH, DORTE VISTISEN, MARTIN B. BLOND, LEA BRUHN NIELSEN, HANAN AMADID, THOMAS F. DEJGAARD, MATHIAS RIED-LARSEN, KRISTIAN KARSTOFT, FREDERIK PERSSON, MARIT E. JØRGENSEN

Diabetes 2019;68(Supplement_1):901-P

https://doi.org/10.2337/db19-901-P

Published: 01 June 2019

View article titled, 901-P: Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

Meeting Abstracts

895-P: Effects of Dapagliflozin, Metformin, or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial

KRISTINE FÆRCH, MARTIN B. BLOND, HANAN AMADID, LEA BRUHN NIELSEN, MARIA TVERMOSEGAARD, MATHIAS RIED-LARSEN, KRISTIAN KARSTOFT, FREDERIK PERSSON, MARIT E. JØRGENSEN

Diabetes 2019;68(Supplement_1):895-P

https://doi.org/10.2337/db19-895-P

Published: 01 June 2019

View article titled, 895-P: Effects of Dapagliflozin, Metformin, or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial

Meeting Abstracts

905-P: Safety, Adherence, and Treatment Satisfaction with Dapagliflozin, Metformin, or Exercise in Individuals with Prediabetes: The Pre-D Trial

HANAN AMADID, MARTIN B. BLOND, LEA BRUHN, KIM K. CLEMMENSEN, CAMILLA T. VAINØ, FREDERIK PERSSON, MARIT E. JØRGENSEN, KRISTINE FÆRCH

Diabetes 2019;68(Supplement_1):905-P

https://doi.org/10.2337/db19-905-P

Published: 01 June 2019

View article titled, 905-P: Safety, Adherence, and Treatment Satisfaction with Dapagliflozin, Metformin, or Exercise in Individuals with Prediabetes: The Pre-D Trial

Meeting Abstracts

526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy

FREDERIK PERSSON, MIE K. EICKHOFF, HARALD MISCHAK, MARIE FRIMODT-MOLLER, PETER ROSSING

Diabetes 2019;68(Supplement_1):526-P

https://doi.org/10.2337/db19-526-P

Published: 01 June 2019

View article titled, 526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy

Journal Articles

Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Petra Zürbig, George Jerums, Peter Hovind, Richard J. MacIsaac, Harald Mischak, Stine E. Nielsen, Sianna Panagiotopoulos, Frederik Persson, Peter Rossing

Diabetes 2012;61(12):3304–3313

https://doi.org/10.2337/db12-0348

Published: 15 November 2012

View article titled, Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Includes: Supplementary data

NARROW

1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

1319-P: Vascular Multimorbidity in Danish Persons with Type 2 Diabetes Is Decreasing, Contributing to Mortality Decline

396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes

866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study

21-OR: Optimization of Albuminuria Lowering Treatment by Crossover Rotation to Four Different Drug Classes

317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial

380-P: Endothelial Glycocalyx Dimensions and Cardiovascular Risk Factors in Type 1 Diabetes

Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture

1615-P: Predicting End-Stage Kidney Disease in Type 1 Diabetes

844-P: Effects of Dapagliflozin, Metformin, or Exercise on Plasma Glucagon Concentrations in Individuals with Prediabetes: The PRE-D Trial

845-P: Changes in Plasma Levels of Liver Enzymes in Response to Dapagliflozin, Metformin, or Exercise in People with Prediabetes: The PRE-D Trial

794-P: “The Tool Created a Chance to Discuss Topics You Don’t Normally Address in Diabetes Consultations”: A Study of Using Patient-Reported Outcomes to Promote Person-Centered Care and Psychosocial Support

137-OR: Trends in Lipid Levels Relative to Lipid-Lowering Drug Use among Danish Type 2 Diabetes Subjects

1467-P: National Trends in the Use of Lipid-Lowering Drugs among Type 2 Diabetes Patients in Denmark from 1997 to 2017

1196-P: The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D)

901-P: Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

895-P: Effects of Dapagliflozin, Metformin, or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial

905-P: Safety, Adherence, and Treatment Satisfaction with Dapagliflozin, Metformin, or Exercise in Individuals with Prediabetes: The Pre-D Trial

526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy

Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only